Focus
Rexulti
An Antipsychotic Drug Gets FDA Green Light Despite Fourfold Higher Risk of Death
For medical professionals, the FDA’s move raises troubling questions about efficacy, safety, and regulatory diligence.
|
An Antipsychotic Drug Gets FDA Green Light Despite Fourfold Higher Risk of Death
For medical professionals, the FDA’s move raises troubling questions about efficacy, safety, and regulatory diligence.
|